eurasian forum slides "the modern understanding of statins from the interventional cardiology point...
TRANSCRIPT
Atheroregression Below Glagov Threshold as New Target of Lipid-Lowering Therapy From Interventional Cardiology Point of View
Atheroregression Below Glagov Threshold as New Target of Lipid-Lowering Therapy From Interventional Cardiology Point of ViewDr. Alexander KharlamovDe Haar Research Foundation, Rotterdam, the Netherlands, NY, NY, USA3rd Department of Internal Medicine/ Ural Institute of Cardiology, Ural Medical University, Yekaterinburg, RussiaScientific and Educational Center Perspective, Ural Medical University, Yekaterinburg, Russia
October, 9th, 2015, Eurasian Forum Medicine, Pharmacy and Public Health, Yekaterinburg, Russia
Outlines
Cardiovascular burden in RussiaRussian national risk factorsLipid-lowering strategy and statinsRegression of atherosclerosis through the centuryNanotechnologies for interventional cardiologyFrontiers of theranostics of atherosclerosisAfter-party impressions from Forum
Part ICardiovascular Burden in RussiaYekaterinburg, Russia, 20136,233 QCAs in 4 PCI centers per year2,877 PCIs (any excl. QCA) per year2,581 stents implanted per year
Ural Medical University
CVD Burden Across the Globe Adapted from The WHO/ U.S. CDCs Atlas of Heart Disease and Stroke, 2015CVDs are the number 1 cause of death globally: more people die annually from CVDs than from any other cause.
An estimated 17.5 million people died from CVDs in 2012, representing 31% of all global deaths. Of these deaths, an estimated 7.4 million were due to coronary heart disease and 6.7 million were due to stroke.
Over three quarters of CVD deaths take place in low- and middle-income countries.
MaleFemaleNichols M, EHJ 2014
CVD Burden in Russia
1,020,000-3,100,000480,000-1,020,000270,000-480,000130,000-270,0000-130,000
CVD burden in Russia, total, 2012Adapted from Bokeria L, et al, 2014
631,852 in Sverdlovsk oblast2,028,179 in Ural Federal District
Total Mortality in Russia (per 1,000) highest in Europe (!): CVD mortality 915.1 (male) vs 516.8 (female) per 100,000CAD mortality 500.9 (male) vs 245.5 (female) per 100,000Adapted from Nichols M, et al, EHJ 2014
Adapted from Mller-Nordhorn J, et al, EHJ 2008Mortality
Shorter Lifespan, and Younger Age of First ACS Manifestation in RussiaAdapted from Bokeria L, et al, 2014
>7065-7063-6560-63